CA2865282A1 - Elevated psma identifies lethal prostate cancers - Google Patents

Elevated psma identifies lethal prostate cancers Download PDF

Info

Publication number
CA2865282A1
CA2865282A1 CA2865282A CA2865282A CA2865282A1 CA 2865282 A1 CA2865282 A1 CA 2865282A1 CA 2865282 A CA2865282 A CA 2865282A CA 2865282 A CA2865282 A CA 2865282A CA 2865282 A1 CA2865282 A1 CA 2865282A1
Authority
CA
Canada
Prior art keywords
psma
imaging
expression
agent
prostate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2865282A
Other languages
English (en)
French (fr)
Inventor
Neil H. Bander
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cornell University
Original Assignee
Cornell University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cornell University filed Critical Cornell University
Publication of CA2865282A1 publication Critical patent/CA2865282A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1072—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from the reproductive system, e.g. ovaria, uterus, testes or prostate
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57555—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Optics & Photonics (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nuclear Medicine (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
CA2865282A 2012-02-24 2013-02-22 Elevated psma identifies lethal prostate cancers Abandoned CA2865282A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261602900P 2012-02-24 2012-02-24
US61/602,900 2012-02-24
PCT/US2013/000045 WO2013126147A2 (en) 2012-02-24 2013-02-22 Elevated psma identifies lethal prostate cancers

Publications (1)

Publication Number Publication Date
CA2865282A1 true CA2865282A1 (en) 2013-08-29

Family

ID=49003541

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2865282A Abandoned CA2865282A1 (en) 2012-02-24 2013-02-22 Elevated psma identifies lethal prostate cancers

Country Status (6)

Country Link
US (2) US20130225541A1 (https=)
EP (2) EP2817629A4 (https=)
JP (2) JP6501524B2 (https=)
CA (1) CA2865282A1 (https=)
HK (1) HK1205788A1 (https=)
WO (1) WO2013126147A2 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013130177A1 (en) * 2012-02-28 2013-09-06 Cornell University Psma as a biomarker for androgen activity in prostate cancer
AU2017348111B2 (en) * 2016-10-27 2023-04-06 Progenics Pharmaceuticals, Inc. Network for medical image analysis, decision support system, and related graphical user interface (GUI) applications
CA3050085A1 (en) 2017-01-20 2018-07-26 Juno Therapeutics Gmbh Cell surface conjugates and related cell compositions and methods
MX2019012017A (es) 2017-04-07 2020-02-12 Juno Therapeutics Inc Celulas modificadas que expresan antigeno de membrana especifico de prostata (psma) o una forma modificada del mismo y metodos relacionados.
US12602772B2 (en) 2018-01-08 2026-04-14 Progenics Pharmaceuticals, Inc. Systems and methods for rapid neural network-based image segmentation and radiopharmaceutical uptake determination
EP4597424A3 (en) 2019-01-07 2025-10-29 Exini Diagnostics AB Systems and methods for platform agnostic whole body image segmentation
BR112021021011A2 (pt) 2019-04-24 2021-12-14 Exini Diagnostics Ab Sistemas e métodos para análise automatizada e interativa de imagens de varredura óssea para detecção de metástases
US12417533B2 (en) 2019-09-27 2025-09-16 Progenics Pharmaceuticals, Inc. Systems and methods for artificial intelligence-based image analysis for cancer assessment
US11900597B2 (en) 2019-09-27 2024-02-13 Progenics Pharmaceuticals, Inc. Systems and methods for artificial intelligence-based image analysis for cancer assessment
BR112022019335A2 (pt) 2020-03-26 2022-11-29 Marigdalia Kaleth Ramirez Fort Método para determinar uma quantidade de energia a ser entregue para provocar um efeito final em uma entidade invasiva-alvo de um alvo em um hospedeiro, método para fornecer terapia a um alvo com o uso de um dispositivo inteligente, método para monitorar um paciente exposto a um carcinógeno conhecido em um evento de exposição, método para tratar adaptativamente um volume de células com irradiação eletromagnética, método para medir a dose absorvida de energia entregue por meio de um alvo dentro de um volume de células, método para permitir regulação ascendente de depravação de androgênio, método para otimizar a dose absorvida de irradiação eletromagnética entregue por meio de um alvo dentro de um volume de células, sistema de terapia para um apêndice de paciente e sistema de terapia para uma cavidade de paciente
US11721428B2 (en) 2020-07-06 2023-08-08 Exini Diagnostics Ab Systems and methods for artificial intelligence-based image analysis for detection and characterization of lesions
CA3231578A1 (en) 2021-10-08 2023-04-13 Exini Diagnostics Ab Systems and methods for automated identification and classification of lesions in local lymph and distant metastases

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE337011T1 (de) * 2001-02-07 2006-09-15 Beth Israel Hospital Modifizierte psma-liganden und deren verwendung
WO2002098897A2 (en) * 2001-06-01 2002-12-12 Cornell Research Foundation, Inc. Modified antibodies to prostate-specific membrane antigen and uses thereof
ATE408712T1 (de) * 2003-01-10 2008-10-15 Millennium Pharm Inc Verfahren zur bestimmung des wiederauftretens von prostata krebs
WO2005021709A2 (en) * 2003-05-29 2005-03-10 Diadexus, Inc. Cln101 antibodies
JP2010507645A (ja) * 2006-10-25 2010-03-11 コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ 前立腺癌を検出するための造影剤
CA2700410C (en) * 2007-10-03 2020-10-06 Cornell University Treatment of proliferative disorders using antibodies to psma
US20110189093A1 (en) * 2008-04-14 2011-08-04 Proscan Rx Pharma Prostate specific membrane antigen antibodies and antigen binding fragments
CN102308212A (zh) * 2008-12-04 2012-01-04 加利福尼亚大学董事会 用于确定前列腺癌诊断和预后的材料和方法
ES2712732T3 (es) * 2009-02-17 2019-05-14 Cornell Res Foundation Inc Métodos y kits para el diagnóstico de cáncer y la predicción de valor terapéutico
WO2010107909A2 (en) * 2009-03-17 2010-09-23 The Johns Hopkins University Methods and compositions for the detection of cancer

Also Published As

Publication number Publication date
EP2817629A2 (en) 2014-12-31
WO2013126147A3 (en) 2014-12-24
WO2013126147A2 (en) 2013-08-29
US20130225541A1 (en) 2013-08-29
JP2019144254A (ja) 2019-08-29
US20180088120A1 (en) 2018-03-29
JP2015513083A (ja) 2015-04-30
EP2817629A4 (en) 2016-01-13
EP3064945A1 (en) 2016-09-07
HK1205788A1 (en) 2015-12-24
JP6501524B2 (ja) 2019-04-17

Similar Documents

Publication Publication Date Title
US20180088120A1 (en) Elevated PSMA Identifies Lethal Prostate Cancers
Donato et al. Improved specificity with 68Ga PSMA PET/CT to detect clinically significant lesions “invisible” on multiparametric MRI of the prostate: a single institution comparative analysis with radical prostatectomy histology
Sadeghi-Naini et al. Early prediction of therapy responses and outcomes in breast cancer patients using quantitative ultrasound spectral texture
Créhange et al. Management of prostate cancer patients with lymph node involvement: a rapidly evolving paradigm
Kinoshita et al. Prognostic significance of hypoxic PET using 18F-FAZA and 62Cu-ATSM in non-small-cell lung cancer
HK1223847A1 (zh) 使用spect/ct分析进行癌症分期的方法
Khandani et al. Positron emission tomography in renal cell carcinoma: an imaging biomarker in development
Liu et al. PET/CT using 68Ga‐PSMA‐617 versus 18F‐fluorodeoxyglucose to differentiate low‐and high‐grade gliomas
Zhou et al. Nucleophosmin 1 overexpression correlates with 18F-FDG PET/CT metabolic parameters and improves diagnostic accuracy in patients with lung adenocarcinoma
Wang et al. Application of near-infrared fluorescence imaging in the accurate assessment of surgical margins during breast-conserving surgery
Dong et al. 18F-PSMA-1007 PET/CT-derived semi-quantitative parameters for risk stratification of newly diagnosed prostate cancer
Brassell et al. Update on magnetic resonance imaging, ProstaScint, and novel imaging in prostate cancer
McBriar et al. Prostate-specific membrane antigen use in glioma management: past, present, and future
Sarkaria et al. Intraoperative molecular imaging with pafolacianine: histologic characteristics of identified nodules
Xiao et al. Evaluation of gastrin-releasing peptide receptor, prostate-specific membrane antigen, and neurotensin receptor 1 as potential biomarkers for accurate prostate cancer stratified diagnosis
Mezi et al. Neuroendocrine tumors of the gallbladder: a case report and review of the literature
Mishra et al. Advanced and futuristic approaches for breast cancer diagnosis
Xu et al. Prediction of tumor biological characteristics in different colorectal cancer liver metastasis animal models using 18F-FDG and 18F-FLT
Patel et al. The challenges of integrating molecular imaging into the optimization of cancer therapy
Jiang et al. Screening of radiotracer for diagnosis of colorectal cancer liver metastasis based on MACC1-SPON2
Kang et al. Sodium/iodide symporter expression in primary lung cancer and comparison with glucose transporter 1 expression
Greco et al. Impact of the diagnostic methods on the therapeutic strategies
Nakamura et al. Diagnostic significance of FDG-PET and argyrophilic nucleolar organizer regions (AgNORs) in oral squamous cell carcinoma
Tao et al. Noninvasive Evaluation of HER2 Expression and Heterogeneity in Urothelial Carcinoma on 68Ga-HER2-affibody PET/CT
Hafez et al. Dynamin-2 and Angiopoietin-like protein 2 as novel prognostic markers in papillary thyroid carcinoma

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20180222

FZDE Discontinued

Effective date: 20201008